Adaptive BiotechnologiesÂ (NASDAQ:ADPT) has begun a virtual clinical study to map the immune responses of people who have contracted COVID-19 or who are likely to have.The second type is a serology test: Using a sample of the patient's blood, this will look for the presence of specific antibodies that are generated by the immune system in response to SARS-CoV-2.